Geode Capital Management
INTS icon

Geode Capital Management’s Intensity Therapeutics INTS Stock Holding History

Geode Capital Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.4K Sell
22,787
-3,232
-12% -$15.2K ﹤0.01% 4114
2026
Q1 		$153K Buy
26,019
+7,609
+41% +$62.1K ﹤0.01% 4009
2025
Q4 		$189K Buy
18,410
+8,054
+78% +$81.7K ﹤0.01% 3925
2025
Q3 		$62.8K Buy
10,356
+7,443
+256% +$53.2K ﹤0.01% 4243
2025
Q2 		$22.4K Sell
2,913
-186
-6% -$3.82K ﹤0.01% 4349
2025
Q1 		$153K Buy
3,099
+525
+20% +$29.2K ﹤0.01% 3920
2024
Q4 		$114K Hold
2,574
– – ﹤0.01% 4066
2024
Q3 		$246K Buy
2,574
+669
+35% +$74.3K ﹤0.01% 3842
2024
Q2 		$233K Hold
1,905
– – ﹤0.01% 3860
2024
Q1 		$248K Buy
1,905
+91
+5% +$10.9K ﹤0.01% 3866
2023
Q4 		$389K Buy
1,814
+891
+97% +$93.8K ﹤0.01% 3710
2023
Q3 		$94.2K Buy
+923
New +$128K ﹤0.01% 4269

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Geode Capital Management's INTS Position: Q2 2026 in Review

Geode Capital Management reduced its Intensity Therapeutics (INTS) stake by 12% in Q2 2026, selling an estimated $15.2K and leaving 22,787 shares worth $93.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4114.

Geode Capital Management first reported a position in INTS in Q3 2023 and has held it in 12 quarters since. The position peaked at $389K in Q4 2023. 14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Geode Capital Management held 22,787 shares of Intensity Therapeutics worth $93.4K as of Q2 2026.
  • Geode Capital Management sold 3,232 Intensity Therapeutics shares in Q2 2026, an estimated $15.2K.
  • Intensity Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4114 holding.
  • Geode Capital Management first reported a position in Intensity Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Geode Capital Management's Intensity Therapeutics position peaked at $389K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.